Vanda Pharmaceuticals Inc (VNDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $241.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Vanda Pharmaceuticals Inc (VNDA) Earnings: Report Dates and Results
Vanda Pharmaceuticals (VNDA) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Vanda Pharmaceuticals reported EPS of -$0.37, above the -$0.72 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VNDA has an expected report date of Feb 9, 2027.
VNDA Earnings Call
The latest VNDA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 38 quarters below that had an estimate, VNDA beat 26, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $69.81M, up 24.1% from $56.26M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.37 | -$0.72 | -$0.83 - -$0.58 | +48.61% | Beat | N/A | 5 | 0 up, 4 down | Oct 28, 2026 | $69.81M |
| Jun 30, 2026 | -$1.04 | -$0.51 | -$0.71 - -$0.49 | -103.92% | Miss | N/A | 4 | 1 up, 4 down | Aug 5, 2026 | $50.53M |
| Mar 31, 2026 | -$0.82 | -$0.69 | -$0.94 - -$0.49 | -18.84% | Miss | N/A | 4 | 0 up, 1 down | May 6, 2026 | $51.72M |
| Dec 31, 2025 | -$2.39 | -$1.32 | -$2.19 - -$0.43 | -81.06% | Miss | N/A | 4 | 0 up, 1 down | Feb 11, 2026 | $57.22M |
| Sep 30, 2025 | -$0.38 | -$0.45 | -$0.61 - -$0.31 | +15.56% | Beat | N/A | 3 | 0 up, 1 down | Oct 29, 2025 | $56.26M |
| Jun 30, 2025 | -$0.46 | -$0.36 | N/A | -27.78% | Miss | N/A | N/A | 0 up, 0 down | Jul 31, 2025 | $52.59M |
| Mar 31, 2025 | -$0.50 | -$0.60 | N/A | +16.67% | Beat | N/A | N/A | 0 up, 0 down | May 7, 2025 | $50.04M |
| Dec 31, 2024 | -$0.08 | -$0.11 | -$0.14 - -$0.05 | +27.27% | Beat | N/A | 3 | 3 up, 0 down | Feb 13, 2025 | $53.19M |
| Sep 30, 2024 | -$0.09 | -$0.16 | -$0.18 - -$0.15 | +43.75% | Beat | -3850.0% | 3 | 0 up, 0 down | Nov 6, 2024 | $47.65M |
| Jun 30, 2024 | -$0.08 | -$0.21 | -$0.21 - -$0.21 | +61.90% | Beat | -366.7% | 1 | 0 up, 1 down | Jul 31, 2024 | $50.47M |
| Mar 31, 2024 | -$0.07 | $0.05 | N/A | -240.00% | Miss | -216.7% | N/A | 0 up, 0 down | May 8, 2024 | $47.46M |
| Dec 31, 2023 | -$0.04 | -$0.09 | -$0.09 - -$0.09 | +55.56% | Beat | -133.3% | 1 | 0 up, 0 down | Feb 7, 2024 | $45.27M |
| Sep 30, 2023 | $0.00 | -$0.04 | -$0.04 - -$0.04 | +106.00% | Beat | -96.0% | 1 | 0 up, 0 down | Nov 8, 2023 | $38.81M |
| Jun 30, 2023 | $0.03 | -$0.13 | -$0.13 - -$0.13 | +123.08% | Beat | -40.0% | 1 | 0 up, 0 down | Jul 27, 2023 | $46.06M |
| Mar 31, 2023 | $0.06 | $0.06 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | May 3, 2023 | $62.50M |
| Dec 31, 2022 | $0.12 | $0.08 | $0.08 - $0.08 | +50.00% | Beat | 0.0% | 1 | 0 up, 0 down | Feb 8, 2023 | $64.48M |
| Sep 30, 2022 | $0.06 | $0.09 | $0.09 - $0.09 | -33.33% | Miss | -57.1% | 1 | 0 up, 0 down | Nov 2, 2022 | $65.32M |
| Jun 30, 2022 | $0.05 | $0.12 | N/A | -58.33% | Miss | -70.6% | 1 | 0 up, 0 down | Aug 3, 2022 | $64.39M |
| Mar 31, 2022 | -$0.11 | -$0.01 | -$0.01 - -$0.01 | -1000.00% | Miss | -173.3% | 1 | 0 up, 1 down | May 5, 2022 | $60.19M |
| Dec 31, 2021 | $0.12 | $0.09 | $0.06 - $0.11 | +33.33% | Beat | -20.0% | 2 | N/A | Feb 23, 2022 | $68.02M |
| Sep 30, 2021 | $0.14 | $0.18 | $0.16 - $0.20 | -22.22% | Miss | +27.3% | 2 | N/A | Nov 3, 2021 | $70.09M |
| Jun 30, 2021 | $0.17 | $0.11 | $0.11 - $0.17 | +54.55% | Beat | +6.3% | 2 | N/A | Jul 28, 2021 | $67.90M |
| Mar 31, 2021 | $0.15 | $0.14 | N/A | +7.14% | Beat | +66.7% | 1 | N/A | May 5, 2021 | $62.67M |
| Dec 31, 2020 | $0.15 | $0.14 | $0.10 - $0.17 | +7.14% | Beat | +87.5% | 2 | N/A | Feb 10, 2021 | $67.65M |
| Sep 30, 2020 | $0.11 | $0.10 | $0.03 - $0.18 | +10.00% | Beat | -94.2% | 3 | N/A | Oct 28, 2020 | $60.31M |
| Jun 30, 2020 | $0.16 | $0.06 | $0.02 - $0.08 | +166.67% | Beat | -42.9% | 3 | N/A | Aug 5, 2020 | $62.21M |
| Mar 31, 2020 | $0.09 | $0.01 | -$0.07 - $0.10 | +800.00% | Beat | +50.0% | 4 | N/A | May 6, 2020 | $58.00M |
| Dec 31, 2019 | $0.08 | $0.11 | $0.04 - $0.20 | -27.27% | Miss | -69.2% | 4 | N/A | Feb 25, 2020 | $60.93M |
| Sep 30, 2019 | $1.91 | $0.07 | $0.01 - $0.14 | N/A | N/A | +855.0% | 4 | N/A | Nov 6, 2019 | $59.48M |
| Jun 30, 2019 | $0.28 | $0.05 | N/A | +460.00% | Beat | +100.0% | 5 | N/A | Jul 31, 2019 | $59.06M |
| Mar 31, 2019 | $0.06 | $0.07 | -$0.01 - $0.17 | -14.29% | Miss | -57.1% | 4 | N/A | May 1, 2019 | $47.71M |
| Dec 31, 2018 | $0.26 | $0.13 | N/A | +100.00% | Beat | +766.7% | 5 | N/A | Feb 13, 2019 | $53.04M |
| Sep 30, 2018 | $0.20 | $0.01 | N/A | N/A | N/A | N/A | 5 | N/A | Nov 7, 2018 | $49.13M |
| Jun 30, 2018 | $0.14 | $0.02 | -$0.54 - $0.04 | +600.00% | Beat | +366.7% | 3 | N/A | Aug 1, 2018 | $47.35M |
| Mar 31, 2018 | $0.14 | -$0.04 | N/A | +450.00% | Beat | N/A | 4 | N/A | May 2, 2018 | $43.59M |
| Dec 31, 2017 | $0.03 | -$0.05 | N/A | +160.00% | Beat | N/A | 5 | N/A | Feb 14, 2018 | $44.28M |
| Sep 30, 2017 | -$0.03 | -$0.05 | N/A | +40.00% | Beat | N/A | 4 | N/A | Nov 7, 2017 | $41.34M |
| Jun 30, 2017 | $0.03 | -$0.20 | -$0.49 - -$0.14 | +115.00% | Beat | N/A | 5 | N/A | Aug 2, 2017 | $42.06M |
| Mar 31, 2017 | -$0.11 | -$0.13 | N/A | +15.38% | Beat | N/A | N/A | N/A | May 2, 2017 | $37.41M |
| Dec 31, 2016 | -$0.01 | -$0.09 | N/A | +88.89% | Beat | N/A | N/A | N/A | Feb 15, 2017 | $38.24M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.73, after -$0.32 the year before. It was -$0.42 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.73 | N/A |
| Dec 31, 2024 | -$0.32 | -710.7% |
| Dec 31, 2023 | $0.05 | -56.3% |
| Dec 31, 2022 | $0.12 | -79.3% |
| Dec 31, 2021 | $0.58 | +13.7% |
| Dec 31, 2020 | $0.51 | -78.1% |
| Dec 31, 2019 | $2.33 | +214.9% |
| Dec 31, 2018 | $0.74 | N/A |
| Dec 31, 2017 | -$0.08 | N/A |
| Dec 31, 2016 | -$0.42 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,733 | 8 | |
| 2026Q2 | Jun 30, 2026 | 5,483 | 7 | |
| 2026Q1 | Mar 31, 2026 | 5,878 | 8 | |
| 2025Q4 | Dec 31, 2025 | 3,445 | 7 | |
| 2025Q3 | Sep 30, 2025 | 5,780 | 6 | |
| 2025Q2 | Jun 30, 2025 | 6,007 | 6 | |
| 2025Q1 | Mar 31, 2025 | 4,644 | 6 | |
| 2024Q4 | Dec 31, 2024 | 7,273 | 6 |
2026Q3 Earnings Call
Opening remarks
Kevin Moran CFO Thanks, Colby. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' third quarter 2026 performance. Our third quarter 2026 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board, and Daniel McGuire, our General Counsel. Following my introductory remarks, Mihael will update you on our ongoing activities. I will then comment on our financial results before we open the lines for your questions. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances, and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors, and management's discussion and analysis of financial condition and results of operations sections of our most recent annual report on Form 10-K, as updated by our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K, and other filings with the SEC, which are available on the SEC's EDGAR system and on our website. We encourage all investors to read these reports and our other filings. The information we provide on this call is provided only as of today, and we undertake no obligation to update or revise publicly any forward-looking statements we may make on this call on account of new information, future events, or otherwise, except as required by law. With that said, I would now like to turn the call over to our CEO, Dr. Mihael Polymeropoulos.
Mihael Polymeropoulos President, CEO, and Chairman Thank you, Kevin. Good afternoon, everyone. Thank you for joining us today for Vanda Pharmaceuticals' third quarter 2026 earnings conference call. We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our newest commercial launch, while operating expenses decreased 18% compared to the second quarter as key phase III and launch preparation activities conclude. Looking ahead, with the commercial launch of BYSANTI expected in the fourth quarter, the Quimilza BLA under FDA review with a December PDUFA date, and positive phase III results supporting potential expansions for NEREUS in GLP-1-induced vomiting and HETLIOZ in delayed sleep-wake phase disorder, we are focused on further moderating costs and driving revenue growth from our current portfolio and planned launches to support sustainable long-term value. Some of our financial highlights on operating expenses.
Frequently Asked Questions About VNDA
When is Vanda Pharmaceuticals's next earnings date?
Vanda Pharmaceuticals's next earnings report is expected for Feb 9, 2027.
Did VNDA beat earnings estimates last quarter?
Yes. Vanda Pharmaceuticals reported EPS of -$0.37 for the quarter ended Sep 30, 2026, above the -$0.72 estimate, a 48.61% surprise.
What EPS do analysts expect from VNDA next quarter?
The consensus EPS estimate for Vanda Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.31 from 7 analysts, with estimates from -$0.38 to -$0.24.
How often does VNDA beat earnings estimates?
Vanda Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -15.44%.
VNDA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts